Germany’s Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

After Halozyme Therapeutics (HALO) confirmed it has submitted a non-binding proposal to the boards of Evotec (EVO) to acquire Evotec for EUR ...

Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German ...

Evotec stock surges 10% as Halozyme Therapeutics expresses takeover interest, sparking investor excitement and speculation in ...

Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s ...

RBC Capital analyst Charles Weston maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of €11.60. The ...

Highlights,The biotech sector sees Evotec becoming a focal point for potential acquisitions, drawing interest from multiple ...

Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...